Skip to main content

Table 4 Distribution of TLR4 alleles and genotypes vitiligo patients and healthy controls (group 2: above 18 years)

From: TLR4 gene polymorphisms in Egyptian vitiligo patients: insights into emerging association with clinical activity, family history, and response to therapy

TLR4 polymorphisms Case (N—76) N (%) Control (N = 81)
N (%)
OR (95% CI) p/pc
rs1927914 (C/T)
CC 12 (15.8) 7 (8.6) 1.98 (0.74–5.34) 0.17/NS
CT 8 (10.5) 22 (27.2) 0.32 (0.13–0.76) 0.01/0.03
TT 56 (73.7) 52 (64.2) 0.64 (0.32–1.27) 0.20/NS
C 32 (21.0) 36 (22.2) 0.93 (0.55–1.60) 0.80/NS
T 120 (79.0) 126 (77.8) 1.07 (0.62–1.83) 0.80/NS
rs1927911 (C/T)
CC 13 (17.1) 26 (32.1) 0.44 (0.21–0.93) 0.03/NS
CT 50 (65.8) 42 (51.9) 1.79 (0.94–3.40) 0.08/NS
TT 13 (17.1) 13 (16.0) 0.93 (0.39–2.15) 0.44/NS
C 76 (50.0) 94 (58.0) 0.72 (0.46–1.13) 0.15/NS
T 76 (50.0) 68 (42.0) 1.38 (0.88–2.16) 0.15/NS
rs11536858 (A/G)
AA 19 (25.0) 20 (24.7) 1.02 (0.49–2.09) 0.96/NS
AG 45 (59.2) 49 (60.5) 0.94 (0.50–1.80) 0.87/NS
GG 12 (15.8) 12 (14.8) 0.93 (0.39–2.21) 0.87/NS
A 83 (54.6) 89 (54.9) 0.99 (0.63–1.54) 0.95/NS
G 69 (45.4) 73 (45.1) 1.01 (0.64–1.58) 0.95/NS
  1. OR odds ratio, 95%CI 95% confidence interval
  2. Significant p/pc values if < 0.05, pc Bonferroni corrected p value (number of comparison × p value). NS non-significant
  3. Fisher’s exact: the CT genotype of rs1927914 was significantly higher in control group